Introduction
Clinical trials of gene therapy for cystic fibrosis (CF) have indicated that the transfer of the CF transmembrane conductance regulator (CFTR) gene can correct the chloride defect in human subjects (reviewed in Ferrari et al 1 ). However, gene transfer efficiency may be too low to result in clinical benefit. This likely relates to a series of extra-and intracellular barriers that the respiratory epithelium has evolved to prevent penetration of lumenally delivered substances. Two different approaches have been adopted to overcome these barriers. The first aims to modify the host by using (i) mucolytic agents, 2 (ii) agents that allow access to the basolateral surface where most of the viral receptors are located 3, 4 or (iii) agents that reduce intracellular degradation of gene transfer agents (GTAs). 5 An alternative strategy involves adding either targeting ligands which can recognise receptors on the apical surface of epithelial cells 6, 7 or motifs which can dock the GTA to the nucleus. 8 Recombinant Sendai virus (SeV) has been developed as a new kind of viral vector in which replication and protein production occur in the cytoplasm, thus avoiding potentially deleterious interactions with the genomic DNA. We have previously shown that recombinant SeV produces efficient gene transfer and expression in airway epithelial cells in vivo, largely because of its ability to overcome some of the barriers mentioned above. SeV is not inhibited by mucus, recognises receptors on the apical surface (sialic acid bound to gangliosides and cholesterol in the membrane) and replicates in the cytoplasm, thus removing the additional barrier of nuclear import. 9 However, the virus used so far in gene transfer studies to the airway epithelium 9, 10 contained all the viral structural genes, thus giving rise to viral particles able to bud out from the infected cell and transduce neighbouring cells. The use of a transmissible SeV in clinical trials of gene therapy may raise important safety concerns because of the transduction of cells in distant organs. The development of a novel nontransmissible defective SeV has recently been reported. 11 The vector does not encode for the envelope fusion protein (F), which is essential for viral entry into cells. During virus preparation, the F protein is supplied in trans. Therefore, the vector is still able to replicate, but is incapable of re-infecting neighbouring cells. The F-defective SeV (SeV/DF) has already been shown to deliver and express reporter genes in a variety of cell types in vitro and in the rat central nervous system. 11 Here we assess the ability of this vector to deliver and express a b-galactosidase (b-gal) reporter gene to airway epithelial cells, both ex vivo and in vivo.
Results

F-defective SeV can infect human nasal epithelial cells
To assess whether SeV/DF was able to infect human cells, nasal epithelial cells freshly obtained from healthy volunteers (n ¼ 8), were infected with SeV-LacZ/DF at a multiplicity of infection (MOI) of 1 and 10. As shown in Figure 1 , only at MOI ¼ 10 SeV/DF produced a significant (Po0.001) increase in b-gal expression compared to untreated cells.
Mucus is not a limiting barrier for SeV/DF
To evaluate the effect of mucus, SeV-LacZ/DF (10 4 -10 7 Cell Infectious Units (CIU)/tissue) was administered to both mucus-covered and mucus-depleted tissues in an ex vivo sheep tracheal epithelium model maintained at an air-liquid interface. As shown in Figure 2 , no b-gal expression was observed in mucus-covered tissues when SeV/DF at a low dose of 10 4 CIU was used. At higher SeV/DF doses, there was a dose-related increase in gene transfer efficiency irrespective of mucus coverage. At 10 6 and 10 7 CIU, mucus depletion produced significantly (Po0.05) greater expression. Importantly, however, even in the presence of mucus SeV/DF can still produce high levels of gene transfer, similar to that observed with F(+) recombinant SeV. 9 Ex vivo gene transfer to non-human primate trachea epithelium
The opportunity arose to assess gene transfer to a nonhuman primate airway epithelium (n ¼ 1) using the same air-liquid interface ex vivo model as for the ovine tissues. SeV-LacZ/DF (10 5 -10 7 CIU/tissue) produced b-gal expression in tissues treated at all titres tested. To evaluate which cells were expressing b-gal, X-gal staining was undertaken. No transgene expression was found in untreated tissues (Figure 3a) . With SeV/DF, b-galexpressing cells were found in the pseudostratified epithelium of both fresh (10 5 CIU: 0.8%; 10 6 CIU: 6.3%; 10 7 CIU: 2.7%) and 'presumed' mucus-depleted tissues after overnight shaking in a waterbath at 371C (10 5 CIU: 3.6%; 10 6 CIU: 6.1%; 10 7 CIU: 10.4%) tissues (Figure 3b ).
F-defective SeV mediates gene transfer to mouse lungs and turbinates in vivo
To assess whether SeV/DF can infect airway epithelial cells in vivo, SeV-LacZ/DF at different doses (7 Â 10 4 , 7 Â 10 6 and 7 Â 10 7 CIU/mouse) was placed in the nasal cavity of Balb/C mice (n ¼ 6), allowing the animals to sniff the bolus into the lungs. Thus, in these studies, the nasal cavity was only very briefly exposed to the b-gal expression in the lungs of the same animals was dose and time dependent (Po0.0001). Again, peak expression was observed at day 2 post-infection (Po0.05), with b-gal values returning to background levels by day 14 ( Figure 5 ).
Effect of contact time
Transmissible SeV-mediated gene transfer requires only brief contact with the airway epithelium. To assess whether the same could be observed with SeV/DF, b-gal expression was evaluated in the nasal turbinates of Balb/C mice (n ¼ 6-8 per group) after either placement of a single bolus within the nasal cavity (cleared within approximately 30 s by sniffing) or by continuous perfusion over approximately 20 min. In both cases, transgene expression was evaluated 48 h later. As shown in Figure  6 , when the virus was administered as a bolus and 'sniffed' into the lungs, significant transgene expression could be observed in nasal turbinates only at the highest titre (7 Â 10 7 CIU). When the virus was perfused over a prolonged contact time, transgene expression was significantly greater at each titre assessed. Even if a three-times lower titre was used (2 Â 10 7 CIU), perfusion over a longer time produced significantly (Po0.001) higher gene expression compared to that when the virus was administered as a bolus at a higher titre (7 Â 10 7 CIU). Thus, although SeV/DF can mediate significant gene transfer with only minimum contact time, in our system higher expression can be obtained with longer periods of contact with the airway epithelium.
Gene transfer efficiency in vivo is comparable to that observed with transmissible-competent F (+)-SeV
To assess whether the inability of the virus to re-infect neighbouring cells produced a decrease in gene transfer efficiency, SeV-LacZ/DF was compared to the wild-type transmission-competent SeV-LacZ in vivo. Balb/C mice (n ¼ 6 per group) were instilled with 5 Â 10 6 CIU/mouse and b-gal expression in the lung analysed at days 2, 7 and 14 post-gene transfer. As shown in Figure 7 , no difference in b-gal expression was observed at day 2. However, significantly (Po0.05) higher expression was observed at day 7 with the transmission-competent virus. For both viruses, b-gal expression reached background levels by day 14.
Discussion
In the present study, we have tested the ability of an F-defective SeV (SeV/DF) vector to infect differentiated airway epithelial cells, both in ex vivo models of differentiated airway epithelium and in vivo. F-defective SeV was able to deliver a LacZ reporter gene to different models of differentiated airway epithelium, Figure 4 Dose-response and time course in the mouse nose after intrapulmonary administration. SeV-LacZ/DF at different titres (7 Â 10 4 , 7 Â 10 6 and 7 Â 10 7 CIU/mouse) was administered to the nose as a single bolus (100 ml) and the solution rapidly sniffed into the lungs of Balb/C mice (n ¼ 6 per group). b-gal expression was assessed 2, 7 or 14 days after gene delivery. ***Po0.0001 when compared to untreated mice. Figure 5 Dose-response and time course in the mouse lung after intrapulmonary administration. SeV-LacZ/DF at different titres (7 Â 10 4 , 7 Â 10 6 and 7 Â 10 7 CIU/mouse) was administered to the nose as a single bolus (100 ml) and the solution rapidly sniffed into the lungs of Balb/C mice (n ¼ 6 per group). b-gal expression was assessed 2, 7 or 14 days after gene delivery. *Po0.05 when compared to untreated mice. 6 and 2 Â 10 7 CIU/mouse in 100 ml) was perfused into the nasal cavity of Balb/C mice (n ¼ 8-9 per group) over a prolonged time (20 min) . At 48 h after gene delivery, b-gal expression in the turbinates was evaluated and compared to that obtained by applying SeV-LacZ/DF (7 Â 10 7 CIU/mouse in 100 ml; n ¼ 6 per group) to the nose as a bolus (cleared within approximately 30 s by sniffing). Error bars indicate s.e.m. ***Po0.001 when 2 Â 10 6 CIU after perfusion were compared to values obtained with 7 Â 10 7 CIU instilled as a bolus. To our knowledge, this is the first time that SeV/DF has been used to infect primate airway epithelial cells in an ex vivo model.
We and others have shown that recombinant Sendai virus can efficiently transfer reporter 9 and therapeutic genes, such as IL-10, 10, 13 to the airway epithelium in vivo. Unlike many other GTAs used so far to target the airway epithelium, SeV is able to overcome many of the extracellular and intracellular barriers limiting gene transfer efficiency. The ability of SeV to mediate gene transfer efficiently is due to the fact that (i) its envelope proteins (F and HN) recognise receptors on the apical surface (cholesterol and sialic acid, respectively), (ii) it is not importantly inhibited by uninfected mucus, (iii) its RNA genome is released in the cytoplasm (no endosomal degradation) and (iv) transcription and translation occur in the cytoplasm (no need for nuclear entry). CF lungs have differing levels and composition of mucus depending on the stage of disease. In the absence of an animal model that mimics such a heterogeneous pattern, it is difficult to assess whether SeV-mediated gene transfer would be differentially inhibited compared to that obtained in the presence of normal uninfected mucus. A major drawback of these previous studies is that the recombinant SeV was transmission-competent and therefore newly formed viral particles can bud out from an infected cell and re-enter the neighbouring cells. Transmissibility of a viral vector has two major implications for gene therapy applications. The first one relates to safety with respect to transduction of distant organs. The second is that antibody and T-cell immune responses are likely to be enhanced when transmissible viruses are used, thus increasing the challenge of repeated administration.
These concerns led to the development of a nontransmissible SeV, in which the F gene is deleted. Newly formed viral particles, budding from a F-nonexpressing cell, are not able to infect neighbouring cells because of the lack of F on the viral envelope. The generation of a transmission-incompetent virus makes SeV a more realistic option for clinical studies. In addition, SeV/DF does not require helper viruses and is therefore not likely to generate wild-type viral particles in a packaging cell line since homologous recombination between RNA genomes has not been observed in nonsegmented negative-strand RNA viruses. Recently, a preclinical safety study was carried out in non-human primates (Mocaca fascicularis) to evaluate the safety profile of a SeV-LacZ/DF after intramuscular administration. Three animals were enrolled in the study, one with the clinically relevant maximal virus dose/kg (3.7 Â 10 8 CIU/ml in 10 ml), the second one with a 10-fold higher dose (3.7 Â 10 9 CIU/ml in 10 ml) and the third one receiving only saline. No significant haematological or histopathological changes were observed, although the animal receiving the highest dose showed a transient increase in white cell count and IL6 (o20 pg/ ml). Furthermore, no virus shedding was observed after RT-PCR of blood and urine samples.
14 These preliminary data have led to the submission in Japan of a clinical protocol involving the use of an F-defective SeV-FGF2 for therapeutic angiogenesis.
One of the main concerns arising when a recombinant defective virus is generated is whether gene transfer efficiency will be altered compared to the wild-type vector. For this reason, SeV/DF was compared to recombinant transmission-competent SeV in vivo at different time points. No difference in b-gal expression in lung homogenate was observed 2 days after gene delivery. Similarly, when an SeV/DF carrying the interleukin 10 (IL-10) gene was compared to a transmissible SeV in vivo, no difference in IL-10 expression was observed in lung homogenate or serum. 15 At day 7 post-infection, a higher gene expression was observed when the transmission-competent SeV was used. Since SeV takes about 18 h to replicate and bud out from infected cells, 16 the higher reporter gene expression is likely to be due to newly formed viral particles re-infecting neighbouring cells. Since the two vectors have similar time-course kinetics and for both expression is much higher than that observed with other GTAs at the same time points, the higher safety risk associated with new viral particles formation makes SeV/DF a better candidate for clinical trials than recombinant F(+) SeV. There is also a theoretical advantage that deleting the F gene may be helpful in reducing immunogenicity and therefore helps repeated administration, although it is likely that many of the other SeV proteins could also be immunogenic.
Another major concern associated with the use of defective viruses is that associated with production. One of the main problems of new viral serotypes or newly pseudotyped lentiviral vectors is the low titre available for in vivo use. In contrast to wild-type SeV, recovery of Differently from other viral vectors, an improved protocol for the generation of high-titre SeV/DF has recently been developed 17 and titres of 10 9 CIU/ml can now be harvested after purification and concentration.
However, despite an improved safety profile, SeV/DF is still likely to cause an immune response, both antibody and T-cell mediated. Viral replication within infected cells and de novo production of viral proteins is likely to lead to enhanced antigen presentation and CTL-mediated destruction of infected cells. Furthermore, in order to use one of these new generation SeV vectors in a clinical trial, a further issue will have to be addressed. Given the transient expression of SeV-mediated gene delivery, these vectors will have to be re-administered. For this reason, protocols based on immunotolerisation or immunosuppression are likely to need to be developed in keeping with other viral vectors. For other GTAs, such as adenoviruses, immunogenicity due to viral products has been diminished by deleting all the viral genes ('gutless' adenovirus) (reviewed in Kochanek et al 18 ). In turn, this has recently led to the development of a new recombinant SeV in which both the genes coding for the matrix (M) and F proteins have been deleted (SeV/DFDM). Lying below the external envelope, the M protein is critically important for virus assembly and budding, and is presumed to interact with viral glycoproteins on the outer envelope and viral nucleocapsid on the inner side. Importantly, the ability of SeV/DFDM to mediate gene transfer both in vitro and in vivo to the lateral ventricle of rat brain was not different from that observed with wild-type SeV. 19 Furthermore, due to the deletion of the M protein gene, the virus is not able to bud out from an infected cell. 20 Thus, since the virus requires only NP, P and L genes for self-replication and transcription of RNP complex, a variety of similar self-replicating deleted SeV vectors defective in M, HN and/or a combination of M, HN and F genes could be designed.
Recently, in order to reduce the formation of nontransmissible virus-like particles (NTVLP), amino-acid substitutions found in temperature-sensitive mutant SeVs were introduced into the M and HN proteins of SeV/DF to generate SeV/M(ts)HN(ts)DF vectors. These mutations allow vector production at low temperatures (321C) and diminished NTVLP formation at 371C. As expected, at 371C the formation of NTVLP by SeV/M(ts)HN(ts)DF was decreased to about 10% of that obtained with SeV/DF. However, the diminished NTVLP formation did not reduce vector-mediated gene expression. 21 In conclusion, we have shown that a newly developed recombinant SeV/DF is as efficient as the recombinant wild-type SeV in delivering reporter genes to differentiated airway epithelium, both in ex vivo models and in vivo. This together with its inability to be transmitted, and the ability to obtain high titres, provide the necessary support for the use of a recombinant cytoplasmic RNA vector in gene therapy clinical trials.
Materials and methods
Virus preparation
The generation and propagation of the recombinant SeV/DF vector carrying the Escherichia coli LacZ reporter gene (SeV-LacZ/DF) was carried out as previously described. 17 The supernatant of LLC-MK2/F7 cells containing infectious particles was subsequently purified, concentrated and stored at À801C. Wild-type recombinant F(+) SeV-LacZ was propagated in embryonated chicken eggs as previously described. 22 Virus titre was determined by infecting LLC-MK2 cells and counting the number of b-gal-expressing cells after X-gal staining. For both viruses, the titre was expressed as CIU per ml.
In vitro gene transfer to human airway epithelial cells
Nasal epithelial cells were collected from healthy human volunteers (n ¼ 8, 22-45 years) by nasal brushing. Cells were washed once in PBS, resuspended in MEM medium (Sigma-Aldrich, Poole, UK) containing 1% penicillin/ streptomycin and plated in a 96-well plate at a density of 290 000 cells/well.
The mean recovery was 1 145 5507148 111 cells/sample, with a percentage of living cells of 20.672.8% after trypan blue exclusion staining. The viability of the nasal cells was also confirmed by phase-contrast microscopic evaluation of ciliary beating. SeV-LacZ/DF was used at MOI ¼ 1 and 10. b-Gal expression was assayed 24 h later.
Ex vivo gene transfer to sheep trachea
Preparation of the ex vivo sheep trachea model and mucus depletion of the epithelium were carried out as previously described. 23 Briefly, the epithelial layer from sheep tracheae (n ¼ 6) was dissected into approximately 0.5 cm 2 pieces and placed at an air-liquid interface. Mucus depletion was carried out by placing the sheep tracheae on a shaking platform in a waterbath at 371C overnight. Scanning electronic microscope analysis showed that the level of mucus coverage decreased from approximately 75% coverage to 25% following mucus depletion. 23 SeV-LacZ/DF at different doses (10 4 -10 7 CIU/tissue) was administered in a final volume of 5 ml. Both fresh and mucus-depleted tissues were then incubated for 48 h before being assessed for b-gal expression.
Ex vivo gene transfer to non-human primate trachea
The trachea from a non-human primate (n ¼ 1, Rhesus, female, 14-15 year old, 6 kg) became available following completion of an unrelated study (Harlan, UK). The trachea was dissected into approximately 0.5 cm 2 pieces and placed at an air-liquid interface as described for the sheep studies. Gene transfer with SeV-LacZ/DF was carried out in the same way as described above for the ex vivo sheep trachea model. b-Gal expression was assessed 48 h later. To evaluate which cells had been transduced, some tissues were stained with X-gal, paraffin-embedded and 5 mm sections were taken. For each dose of SeV-LacZ/DF, only one representative section was analysed from each piece (n ¼ 1 per dose). b-Galexpressing cells were quantified microscopically by point counting the whole airway epithelium section.
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In vivo gene transfer
All in vivo experiments were carried out in Balb/C mice (male, 6-8 weeks, n ¼ 6 per group). Intrapulmonary administration ('sniffing') was carried out as follows: recombinant SeV-LacZ/DF (7 Â 10 4 -7 Â 10 7 CIU/mouse) was placed as a single 100 ml bolus into the nasal cavity and the solution was sniffed into the lungs. 24 For nasal perfusion, a fine-tip catheter (outer diameter: 0.5 mm) was placed 5 mm within the nasal cavity and 100 ml of the solution containing SeV-LacZ/DF (2Â 10 6 and 2 Â 10 7 CIU/mouse) or balanced salt solution (137 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH 7.6) perfused at a rate of 5 ml/min using a peristaltic pump (P1 pump, Pharmacia, Herts, UK). For experiments comparing the efficiency of SeV-LacZ/DF and wild-type SeV-LacZ, a dose of 5 Â 10 6 CIU/mouse in a final volume of 100 ml was sniffed into the lungs of Balb/C mice (n ¼ 6). Transgene expression was evaluated at days 2, 7 and 14 post-administration.
Reporter gene expression assay
Cells and tissues (turbinate, trachea, lung) were homogenised in an appropriate volume of lysis buffer (0.25 M Tris-HCl, pH 7.4, 0.1% Triton X-100). Following three freeze/thaw cycles, the lysates were spun for 10 min at 13 000 rpm and the supernatant assayed for b-gal activity using a chemiluminescent assay (Clontech, Hampshire, UK). X-Gal staining was carried out as previously described. 25 
Statistical analysis
All values are expressed as mean7s.e.m. for convenience and n refers to the number of animals or tissue culture samples used. Data were compared using independent Student's t-test after confirmation of normal distribution. In isolated cases, a log transformation was carried out. A one-way ANOVA with Dunnett's test was carried out in Figure 5 . The null hypothesis was rejected at Po0.05.
